97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004812-40-GB12/04/201221/03/2012Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2Czech Republic;Netherlands;Germany;Italy;United Kingdom
2NCT01482884March 201229/11/2011Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative ColitisA Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative ColitisUlcerative ColitisDrug: tralokinumab;Drug: placeboAstraZenecaMedImmune LtdCompleted18 Years65 YearsAll147Phase 2Czech Republic;France;Germany;Italy;Poland;United Kingdom;Netherlands
3EUCTR2011-004812-40-DE26/01/201225/11/2011Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2Czech Republic;Netherlands;Germany;United Kingdom;Italy
4EUCTR2011-004812-40-NL25/01/201222/12/2011Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 15.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2Czech Republic;Netherlands;United Kingdom;Italy
5EUCTR2011-004812-40-CZ24/01/201229/12/2011Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2Czech Republic;Netherlands;United Kingdom;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2011-004812-40-IT12/12/201102/03/2012A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitisA phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1Level: LLTClassification code 10045282Term: UCSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
Other descriptive name: NA
ASTRAZENECANULLNot RecruitingFemale: yes
Male: yes
110Phase 2Czech Republic;Netherlands;Germany;United Kingdom;Italy